Show simple item record

dc.contributor.authorMoutal, Aubin
dc.contributor.authorChew, Lindsey A
dc.contributor.authorYang, Xiaofang
dc.contributor.authorWang, Yue
dc.contributor.authorYeon, Seul Ki
dc.contributor.authorTelemi, Edwin
dc.contributor.authorMeroueh, Seeneen
dc.contributor.authorPark, Ki Duk
dc.contributor.authorShrinivasan, Raghuraman
dc.contributor.authorGilbraith, Kerry B
dc.contributor.authorQu, Chaoling
dc.contributor.authorXie, Jennifer Y
dc.contributor.authorPatwardhan, Amol
dc.contributor.authorVanderah, Todd W
dc.contributor.authorKhanna, May
dc.contributor.authorPorreca, Frank
dc.contributor.authorKhanna, Rajesh
dc.date.accessioned2016-11-02T18:52:36Z
dc.date.available2016-11-02T18:52:36Z
dc.date.issued2016-07
dc.identifier.citation(S)-lacosamide inhibition of CRMP2 phosphorylation reduces postoperative and neuropathic pain behaviors through distinct classes of sensory neurons identified by constellation pharmacology. 2016, 157 (7):1448-63 Painen
dc.identifier.issn1872-6623
dc.identifier.pmid26967696
dc.identifier.doi10.1097/j.pain.0000000000000555
dc.identifier.urihttp://hdl.handle.net/10150/621224
dc.description.abstractChronic pain affects the life of millions of people. Current treatments have deleterious side effects. We have advanced a strategy for targeting protein interactions which regulate the N-type voltage-gated calcium (CaV2.2) channel as an alternative to direct channel block. Peptides uncoupling CaV2.2 interactions with the axonal collapsin response mediator protein 2 (CRMP2) were antinociceptive without effects on memory, depression, and reward/addiction. A search for small molecules that could recapitulate uncoupling of the CaV2.2-CRMP2 interaction identified (S)-lacosamide [(S)-LCM], the inactive enantiomer of the Food and Drug Administration-approved antiepileptic drug (R)-lacosamide [(R)-LCM, Vimpat]. We show that (S)-LCM, but not (R)-LCM, inhibits CRMP2 phosphorylation by cyclin dependent kinase 5, a step necessary for driving CaV2.2 activity, in sensory neurons. (S)-lacosamide inhibited depolarization-induced Ca influx with a low micromolar IC50. Voltage-clamp electrophysiology experiments demonstrated a commensurate reduction in Ca currents in sensory neurons after an acute application of (S)-LCM. Using constellation pharmacology, a recently described high content phenotypic screening platform for functional fingerprinting of neurons that uses subtype-selective pharmacological agents to elucidate cell-specific combinations (constellations) of key signaling proteins that define specific cell types, we investigated if (S)-LCM preferentially acts on certain types of neurons. (S)-lacosamide decreased the dorsal root ganglion neurons responding to mustard oil, and increased the number of cells responding to menthol. Finally, (S)-LCM reversed thermal hypersensitivity and mechanical allodynia in a model of postoperative pain, and 2 models of neuropathic pain. Thus, using (S)-LCM to inhibit CRMP2 phosphorylation is a novel and efficient strategy to treat pain, which works by targeting specific sensory neuron populations.
dc.description.sponsorshipArizona Health Science Center; American Heart Association [SDG5280023]; Department of Defense Congressionally Directed Military Medical Research and Development Program [NF1000099]; Children's Tumor Foundation NF1 Synodos grant [2015-04-009A]; Children's Tumor Foundation; Flinn Scholarship; University of Arizona Undergraduate Biology Research Program; University of Arizona Undergraduate Honors College; University of Arizona Neuroscience and Cognitive Science Undergraduate fund; Medical Student Research Program from the National Institutes of Healthen
dc.language.isoenen
dc.publisherLIPPINCOTT WILLIAMS & WILKINSen
dc.relation.urlhttp://journals.lww.com/pain/Citation/2016/07000/_S__lacosamide_inhibition_of_CRMP2_phosphorylation.11.aspxen
dc.rightsCopyright: © 2016 International Association for the Study of Pain.en
dc.rights.urihttp://rightsstatements.org/vocab/InC/1.0/
dc.subjectCaV2.2en
dc.subjectCRMP2en
dc.subject(S)-lacosamideen
dc.subjectConstellation pharmacologyen
dc.subjectCalcium imagingen
dc.subjectPostoperative painen
dc.subjectNeuropathic painen
dc.title(S)-lacosamide inhibition of CRMP2 phosphorylation reduces postoperative and neuropathic pain behaviors through distinct classes of sensory neurons identified by constellation pharmacology.en
dc.typeArticleen
dc.contributor.departmentUniv Arizona, Coll Med, Dept Pharmacolen
dc.identifier.journalPainen
dc.description.note12 month embargoen
dc.description.collectioninformationThis item from the UA Faculty Publications collection is made available by the University of Arizona with support from the University of Arizona Libraries. If you have questions, please contact us at repository@u.library.arizona.edu.en
dc.eprint.versionFinal accepted manuscripten
refterms.dateFOA2017-08-01T00:00:00Z
html.description.abstractChronic pain affects the life of millions of people. Current treatments have deleterious side effects. We have advanced a strategy for targeting protein interactions which regulate the N-type voltage-gated calcium (CaV2.2) channel as an alternative to direct channel block. Peptides uncoupling CaV2.2 interactions with the axonal collapsin response mediator protein 2 (CRMP2) were antinociceptive without effects on memory, depression, and reward/addiction. A search for small molecules that could recapitulate uncoupling of the CaV2.2-CRMP2 interaction identified (S)-lacosamide [(S)-LCM], the inactive enantiomer of the Food and Drug Administration-approved antiepileptic drug (R)-lacosamide [(R)-LCM, Vimpat]. We show that (S)-LCM, but not (R)-LCM, inhibits CRMP2 phosphorylation by cyclin dependent kinase 5, a step necessary for driving CaV2.2 activity, in sensory neurons. (S)-lacosamide inhibited depolarization-induced Ca influx with a low micromolar IC50. Voltage-clamp electrophysiology experiments demonstrated a commensurate reduction in Ca currents in sensory neurons after an acute application of (S)-LCM. Using constellation pharmacology, a recently described high content phenotypic screening platform for functional fingerprinting of neurons that uses subtype-selective pharmacological agents to elucidate cell-specific combinations (constellations) of key signaling proteins that define specific cell types, we investigated if (S)-LCM preferentially acts on certain types of neurons. (S)-lacosamide decreased the dorsal root ganglion neurons responding to mustard oil, and increased the number of cells responding to menthol. Finally, (S)-LCM reversed thermal hypersensitivity and mechanical allodynia in a model of postoperative pain, and 2 models of neuropathic pain. Thus, using (S)-LCM to inhibit CRMP2 phosphorylation is a novel and efficient strategy to treat pain, which works by targeting specific sensory neuron populations.


Files in this item

Thumbnail
Name:
Accepted-00006396-900000000-99 ...
Size:
4.659Mb
Format:
PDF
Description:
Final Accepted Manuscript

This item appears in the following Collection(s)

Show simple item record